fluconazole and anidulafungin

fluconazole has been researched along with anidulafungin in 104 studies

Research

Studies (104)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (4.81)	18.2507
2000's	28 (26.92)	29.6817
2010's	48 (46.15)	24.3611
2020's	23 (22.12)	2.80

Authors

Authors	Studies
Alastruey-Izquierdo, A; Almirante, B; Cuenca-Estrella, M; Gomez-Lopez, A; Pahissa, A; Rodriguez, D; Rodriguez-Tudela, JL	1
Chapman, SW; Cleary, JD; Garcia-Effron, G; Perlin, DS	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chu, CC; Hsueh, PR; Ruan, SY	1
Garcia-Effron, G; Kontoyiannis, DP; Lewis, RE; Perlin, DS	1
Arendrup, MC; Bruun, B; Buzina, W; Garcia-Effron, G; Jensen, HE; Lass-Flörl, C; Lundin, C; Mortensen, KL; Perlin, DS; Reiter, N	1
Dimopoulos, G; Falagas, ME; Velegraki, A	1
Chen, E; Ostrosky-Zeichner, L; Paetznick, VL; Rodriguez, J; Sheehan, DJ	1
Buitrago, MJ; Cuenca-Estrella, M; Gomez-Lopez, A; Mellado, E; Monzon, A; Rodriguez-Tudela, JL	1
Chittick, P; Delashmitt, B; Evans, J; Palavecino, EL; Peacock, JE	1
Badali, H; De Hoog, GS; Illnait-Zaragozi, MT; Meis, JF; Najafzadeh, MJ	1
Holtappels, M; Kucharíková, S; Lagrou, K; Tournu, H; Van Dijck, P	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Arikan, S; Cetinkaya, Y; Kocagöz, S; Unal, S; Uzun, O	1
Galgiani, JN; Krishnarao, TV	1
Balko, TV; Harding, GA; Hoban, DJ; Kabani, A; Karlowsky, JA; Turik, M; Zelenitsky, SA; Zhanel, GG	1
Jones, RN; Marco, F; Messer, SA; Pfaller, MA	1
Bacher, J; Bell, A; Candelario, M; Groll, AH; Lyman, CA; McMillian, CL; Petraitiene, R; Petraitis, V; Sein, T; Walsh, TJ	1
Ernst, EJ; Klepser, ME; Pfaller, MA	1
Cuenca-Estrella, M; Díaz-Guerra, TM; Mellado, E; Monzón, A; Rodríguez-Tudela, JL	1
Bacher, J; Francesconi, A; Groll, AH; Lyman, CA; Petraitiene, R; Petraitis, V; Piscitelli, SC; Schaufele, RL; Sein, T; Walsh, TJ	1
Denning, DW; Moore, CB; Oakley, KL	1
Ernst, EJ; Klepser, ME; Lewis, RE; Pfaller, MA; Roling, EE; Wasson, A	1
Goldstein, BP; Henkel, T; Krause, DS; Simjee, AE; van Rensburg, C; Viljoen, J; Walsh, TJ; Wible, M	1
Steinbach, WJ	1
Boyken, L; Diekema, DJ; Hollis, RJ; Messer, SA; Pfaller, MA; Tendolkar, S	1
Deziel, MR; Drusano, GL; Drusano, MF; Gumbo, T; Liu, W; Louie, A; Ma, L	1
Betts, R; Chapman, SW; Goldstein, BP; Kett, DH; Krause, DS; Kumar, D; Pappas, PG; Reboli, AC; Rotstein, C; Schranz, J; Walsh, TJ; Wible, M	1
Revankar, SG; Sobel, JD	1
Aberegg, SK; O'Brien, JM	1
Moses, AE; Nir-Paz, R	1
Clemons, KV; Martinez, M; Stevens, DA; Tong, AJ; van Asbeck, E	1
Cubillos, GF; Kett, DH	1
Cooper, C; Mills, EJ; Nachega, JB; Perri, D; Phillips, P; Tleyjeh, I; Wu, P	1
Almirante, B; Pemán, J	1
Borges Sá, M; Garnacho Montero, J	1
Chandrasekar, PH; Cutright, JL; Krishnan-Natesan, S; Manavathu, EK	1
Arnold, TM; Dotson, E; Hage, CA; Sarosi, GA	1
Venditti, M	1
Cervera, C; Escorsell, A; Linares, L; Moreno, A; Reverté, E	1
De Rosa, FG; Falcone, M; Ghezzi, MC; Pasero, D; Raponi, G; Russo, A; Toma, L; Venditti, M	1
Andes, D; Arendrup, MC; Brown, SD; Diekema, DJ; Lockhart, SR; Motyl, M; Perlin, DS; Pfaller, MA	1
Cantón, E; Espinel-Ingroff, A	1
Cartier, S; Chambers, R; Kett, DH; Maschio, M; Reboli, AC; Rotstein, C; Tarallo, M	1
Chen, SC; Kong, DC; Liew, D; Marriott, D; Morrissey, O; Neoh, CF; Slavin, M; Stewart, K	1
Biswas, P; Kett, DH; Pappas, PG; Reboli, AC; Reisman, AL; Rotstein, C; Schlamm, HT; Shorr, AF; Walsh, TJ	1
Biswas, P; Kett, DH; Reboli, AC; Reisman, AL; Schlamm, HT; Shorr, AF	1
De Rosa, FG; Di Perri, G; Manzione, NA; Messina, M; Ottobrelli, A; Ranghino, A; Raviolo, S; Segoloni, GP	1
Bocanegra, R; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Wiederhold, NP	1
Auzinger, G; Borges Sá, M; Dimopoulos, G; Grigoras, I; Kantecki, M; Marček, T; Meersseman, W; Menichetti, F; Miller, PJ; Montravers, P; Pachl, J; Paiva, JA; Ruhnke, M; Sganga, G	1
Alves, SH; Antunes, MS; Bandeira, LA; Denardi, LB; Mario, DA; Santurio, JM; Severo, LC	1
Caggiano, G; Carone, A; Corbo, F; Franchini, C; Montagna, MT; Muraglia, M; Piarulli, M; Rosato, A; Schiavone, BI	1
Chen, HT; Chu, WL; Lin, CC; Lo, HJ; Yang, YL	1
Gardiner, BJ; Korman, TM; Slavin, MA; Stuart, RL	1
Arendrup, MC; Cuenca-Estrella, M; Hope, WW; Lass-Flörl, C	1
Biswas, P; Chin-Hong, P; Kett, DH; Pappas, PG; Patterson, TF; Reboli, AC; Reinhardt, J; Swanson, R; Tobin, E; Vazquez, J	1
Borens, O; Furustrand Tafin, U; Maiolo, EM; Trampuz, A	1
Gil-Gómez, I; Lorente-Fernández, L; Monte-Boquet, E; Poveda-Andrés, JL; Ruiz-Ramos, J; Salavert-Lleti, M	1
Beldavs, ZG; Bolden, CB; Chiller, TM; Cleveland, AA; Farley, MM; Harrison, LH; Iqbal, N; Kuykendall, RJ; Lockhart, SR; Park, BJ; Pham, CD; Schaffner, W	1
Cattel, F; Corcione, S; D'Avolio, A; De Rosa, FG; Di Perri, G; Motta, I	1
Cornely, OA; Franke, B; Glossmann, J; Heimann, SM; Kochanek, M; Langebartels, G; Padosch, SA; Reiner, M; Reuter, H; Seifert, H; Stippel, D; Vehreschild, JJ; Vehreschild, MJ; Vierzig, A; Wisplinghoff, H	1
Busuttil, RW; Limaye, AP; Meneses, K; Morris, MI; Pelletier, S; Safdar, N; Singh, N; Winston, DJ	1
Badali, H; de Hoog, GS; Mashedi, O; Meis, JF; Mohammadi, R	1
Akova, M; Bassetti, M; De Waele, JJ; Dimopoulos, G; Kaukonen, KM; Koulenti, D; Lipman, J; Martin, C; Montravers, P; Rello, J; Rhodes, A; Roberts, JA; Sinnollareddy, MG; Starr, T; Wallis, SC	1
Chlebicki, MP; Kwa, AL; Lee, W; Liew, YX; Ngan, CC; Tan, AL; Teo, J; Too, IA	1
Badali, H; Chowdhary, A; de Hoog, GS; Fakhim, H; Khodavaisy, S; Meis, JF	1
Auzinger, G; Charbonneau, C; Graham, CN; Kantecki, M; Knox, HN; Playford, EG; Schlamm, H; Weinstein, D	1
Groeneveld, AB; Rijnders, BJ; van der Geest, PJ; Vonk, AG	1
Arslan, U; Dagi, HT; Findik, D; Senkeles, C	1
Ahmad, N; Ginsapu, SJ; Gowbei, A; Hashim, R; Ho Betty, LS; Ramli, NY; Razak, MF; Sabaratnam, P; Sipiczki, M; Suppiah, J; Tap, RM	1
Hsueh, PR; Wang, H; Xu, YC	1
Barber, KE; Cretella, D; King, ST; Stover, KR	1
Arthur, I; Baird, R; Bak, N; Blyth, C; Botes, J; Chapman, B; Chen, S; Cheong, E; Cooley, L; George, CR; Goeman, E; Hajkowicz, K; Halliday, C; Heath, CH; Hofmeyr, A; Kalukottege, P; Keighley, C; Kennedy, K; Kesson, A; Kidd, S; Korman, TM; Leung, M; Liu, E; Macesic, N; Marriott, D; McMullan, B; Morrissey, CO; Pendle, S; Robson, J; Slavin, M; Sorrell, TC; Underwood, N; van Hal, S; Weeks, K	1
Agurto, C; Bustamante, B; Diaz, A; Hidalgo, J; Huaroto, L; Illescas, R; Ramirez, R; Rodriguez, L	1
Aram, J; Bassetti, M; Capparella, MR; Hogan, PA; Kontoyiannis, DP; Nucci, M; Yan, JL	1
Charbonneau, C; Chen, YC; Lee, TY; Ou, HT	1
Dinleyici, EC; Kara, A; Kong, DCM; Neoh, CF; Senol, E; Turner, SJ	1
De Carolis, E; Mello, E; Perlin, DS; Posteraro, B; Sanglard, D; Sanguinetti, M; Vella, A	1
Eraso, E; Gil-Alonso, S; Jauregizar, N; Marcos-Arias, C; Mateo, E; Quindós, G; Sevillano, E	1
Ataollahy, N; Hammarström, H; Kondori, N; Lindberg, E	1
Chaftari, AM; Hachem, R; Kontoyiannis, DP; Raad, II; Reitzel, RA; Rosenblatt, J; Vargas-Cruz, N; Wilson Dib, R	1
Borman, AM; Fraser, M; Johnson, EM; Muller, J; Palmer, MD; Patterson, Z; Szekely, A; Walsh-Quantick, J	1
Akdağ, D; Ener, B; Işıkgöz Taşbakan, M; Metin, DY; Pullukçu, H; Sipahi, OR; Yamazhan, T	1
An, MM; Chen, SM; Guo, SY; Hou, WT; Hu, XY; Jiang, YY; Qiu, XR; Shen, H; Song, LJ; Zhang, Y; Zou, Z	1
Chen, J; Chu, Y; Han, X; Shang, H; Tian, S; Wang, Q; Zhou, B	1
Aram, JA; Busca, A; Capparella, MR; De Rosa, FG; Yan, JL	1
Brandão, IB; Colombo, AL; de Almeida, SLR; de Andrade, TS; de Miranda Costa, MM; de Oliveira Dias, P; de Souza Jordão, RT; Francisco, EC; Meis, JF; Nobrega de Almeida, J; Pereira, FM; Santos Ferreira, F	1
Fuchs, F; Hamprecht, A; Hof, H; Hofmann, S; Kurzai, O; Meis, JF	1
Beyer, R; Gabaldón, T; Ksiezopolska, E; Nunez-Rodriguez, JC; Schikora-Tamarit, MÀ; Schüller, C	1
Farooqi, J; Jabeen, K; Memon, S; Naqvi, SF; Zafar, A; Zafar, U	1
Chen, H; Chen, X; Deng, S; Hong, N; Hu, D; Lei, Y; Liao, W; Tsui, KM; Wu, G; Yan, L; Yu, N; Zhang, H; Zhao, R	1
Arendrup, MC; Georgiou, PC; Meletiadis, J	1
Alanio, A; Denis, B; Fuchs, F; Hamane, S; Knoll, MA; Koehler, P; Krause, R; Lackner, N; Lass-Flörl, C; Rath, PM; Samardzic, E; Steinmann, J; Ulmer, H; Verhasselt, HL	1
Abastabar, M; Aghili, SR; Badali, H; Haghani, I; Hedayati, MT; Javidnia, J; Khojasteh, S; Meis, JF; Moazeni, M; Nargesi, S; Nosratabadi, M; Shabanzadeh, S; Shokohi, T; Zaedi, A	1
Cao, W; Lan, C; Liu, Y; Qin, S; Qin, Z; Zhang, P; Zhang, Z	1
Aksaray, S; Turan, D	1
Bilal, H; Hou, B; Islam, R; Khan, MN; Khan, RU; Shafiq, M; Zeng, Y	1
Balázs, B; Balogh, B; Bozó, A; Forgács, L; Kelentey, B; Kovács, R; Majoros, L; Tóth, Z	1
Gonçalves, GA; Kraft, L; Ribeiro, VST; Suss, PH; Tuon, FF	1
Enersen, M; Fjeld, KG; Gay, CL; Herlofson, BB; Hove, LH; Kristoffersen, AK; Lerdal, A; Monsen, RE; Nordgarden, H; Tollisen, A	1
He, C; Kang, W; Li, J; Wang, T; Xu, Y; Yu, J; Zhang, G; Zhang, J; Zhao, Y	1
Abastabar, M; Badiee, P; Haghani, I; Mohammadi, R; Morovati, H; Noorbakhsh, M; Sharifi, M	1
Abdorahimi, M; Ahmadikia, K; Badali, H; Gharehbolagh, SA; Khodavaisy, S; Mahmoudi, S; Meis, JF; Rezaie, S	1
Melo, RDCB; Mendes, FR; Rego, EM; Rocha, V; Silva, WFD; Velloso, EDRP	1

Reviews

16 review(s) available for fluconazole and anidulafungin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Antifungal agents in children. Pediatric clinics of North America, 2005, Volume: 52, Issue:3 Topics: Age Factors; Amphotericin B; Anidulafungin; Antifungal Agents; Caspofungin; Chemistry, Pharmaceutical; Child; Clinical Trials as Topic; Drug Approval; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Patient Selection; Pediatrics; Peptides, Cyclic; Pyrimidines; Safety; Thiazoles; Triazoles; United States; Voriconazole	2005
Anidulafungin in the treatment of patients with invasive candidiasis. International journal of antimicrobial agents, 2008, Volume: 32 Suppl 2 Topics: Anidulafungin; Antifungal Agents; Candida; Candidiasis; Echinocandins; Fluconazole; Humans; Pyrimidines; Triazoles; Voriconazole	2008
Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. Annals of clinical microbiology and antimicrobials, 2009, Jun-26, Volume: 8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Anidulafungin; Antifungal Agents; Azoles; Candidiasis; Echinocandins; Fluconazole; Humans; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult	2009
[Current treatment of candidemia. Role of anidulafungin]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 14 Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Candidiasis; Clinical Trials as Topic; Disease Susceptibility; Double-Blind Method; Drug Resistance, Fungal; Echinocandins; Fluconazole; Fungemia; Gastrointestinal Diseases; Global Health; Humans; Middle Aged; Multicenter Studies as Topic; Neutropenia; Risk Factors; Species Specificity	2008
[Role of anidulafungin in critically ill patients]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 14 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candidiasis; Clinical Trials as Topic; Critical Illness; Cross Infection; Drug Therapy, Combination; Echinocandins; Fluconazole; Fungemia; Humans; Immunocompetence; Intensive Care Units; Itraconazole; Practice Guidelines as Topic	2008
Traditional and emerging antifungal therapies. Proceedings of the American Thoracic Society, 2010, Volume: 7, Issue:3 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Caspofungin; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Micafungin; Pyrimidines; Triazoles; Voriconazole	2010
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2011, Volume: 14, Issue:3 Topics: Anidulafungin; Antifungal Agents; beta-Glucans; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Glucosyltransferases; Humans; Inhibitory Concentration 50; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Mutation; Proteoglycans; Randomized Controlled Trials as Topic; Species Specificity; Treatment Outcome	2011
In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same? Enfermedades infecciosas y microbiologia clinica, 2011, Volume: 29 Suppl 2 Topics: Anidulafungin; Candida; Candidiasis; Caspofungin; Drug Evaluation, Preclinical; Drug Resistance, Fungal; Drug Resistance, Multiple, Fungal; Echinocandins; Fluconazole; Fungal Proteins; Glucosyltransferases; Humans; In Vitro Techniques; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Species Specificity; Therapeutic Equivalency	2011
Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines. Le infezioni in medicina, 2014, Volume: 22, Issue:2 Topics: Anidulafungin; Antifungal Agents; Candida; Candidiasis; Cross Infection; Echinocandins; Europe; Fluconazole; Guidelines as Topic; Humans; Italy; Randomized Controlled Trials as Topic; Treatment Outcome; United States	2014
Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region. Future microbiology, 2016, Volume: 11 Topics: Anidulafungin; Antifungal Agents; Asia; Azoles; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidemia; Candidiasis; Candidiasis, Invasive; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Incidence; Itraconazole; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Phenotype; Prevalence; Voriconazole	2016
Therapeutic tools for oral candidiasis: Current and new antifungal drugs. Medicina oral, patologia oral y cirugia bucal, 2019, Mar-01, Volume: 24, Issue:2 Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Amphotericin B; Anidulafungin; Antifungal Agents; Azoles; Candidiasis, Oral; Caspofungin; Clotrimazole; Databases, Factual; Drug Interactions; Echinocandins; Fluconazole; Humans; Miconazole; Nitriles; Nystatin; Pyridines; Triazoles	2019
Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris. BMC infectious diseases, 2020, Nov-11, Volume: 20, Issue:1 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candidiasis; Caspofungin; Drug Resistance, Multiple, Fungal; Fluconazole; Humans; Micafungin; Prevalence	2020
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fluconazole; Humans; Neoplasms; Treatment Outcome; Voriconazole	2021
Efficacy of anti-fungal agents for invasive fungal infection prophylaxis in liver transplant recipients: A network meta-analysis. Mycoses, 2022, Volume: 65, Issue:10 Topics: Anidulafungin; Antifungal Agents; Echinocandins; Fluconazole; Humans; Invasive Fungal Infections; Itraconazole; Liver Transplantation; Mycoses; Network Meta-Analysis; Randomized Controlled Trials as Topic; Transplant Recipients	2022
Distribution and antifungal susceptibility pattern of Virulence, 2022, Volume: 13, Issue:1 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Candida tropicalis; Candidiasis; Echinocandins; Fluconazole; Humans; Microbial Sensitivity Tests	2022

Trials

8 trial(s) available for fluconazole and anidulafungin

Article	Year
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Sep-15, Volume: 39, Issue:6 Topics: Administration, Oral; Adult; Aged; Anidulafungin; Antifungal Agents; Candidiasis; Double-Blind Method; Echinocandins; Esophageal Diseases; Female; Fluconazole; Humans; Infusions, Intravenous; Male; Middle Aged; Peptides, Cyclic	2004
Anidulafungin versus fluconazole for invasive candidiasis. The New England journal of medicine, 2007, Jun-14, Volume: 356, Issue:24 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candida; Candidiasis; Double-Blind Method; Echinocandins; Female; Fluconazole; Fungemia; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Peptides, Cyclic; Treatment Outcome	2007
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC infectious diseases, 2011, Sep-30, Volume: 11 Topics: Anidulafungin; Antifungal Agents; Candida albicans; Candidiasis, Invasive; Echinocandins; Fluconazole; Humans; Multivariate Analysis; Survival Analysis; Treatment Outcome	2011
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Critical care (London, England), 2011, Volume: 15, Issue:5 Topics: Aged; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Double-Blind Method; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Severity of Illness Index; Societies, Medical; Treatment Outcome; United States	2011
Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012, Volume: 18, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candida; Candidiasis, Invasive; Critical Illness; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Prospective Studies; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole	2012
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC infectious diseases, 2014, Feb-21, Volume: 14 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candida; Candidemia; Candidiasis; Candidiasis, Invasive; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Republic of Korea; Research Design; Risk; Treatment Outcome; United States; Voriconazole; Young Adult	2014
Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014, Volume: 14, Issue:12 Topics: Adolescent; Adult; Aged; Anidulafungin; Antibiotic Prophylaxis; Antifungal Agents; Double-Blind Method; Echinocandins; Female; Fluconazole; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Immunocompromised Host; Incidence; Liver Diseases; Liver Transplantation; Male; Middle Aged; Mycoses; Postoperative Complications; Prognosis; Risk Factors; Survival Rate; Transplant Recipients; United States; Young Adult	2014
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis; Candidemia; Candidiasis, Invasive; Clinical Trials as Topic; Echinocandins; Female; Fluconazole; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Treatment Outcome	2017

Other Studies

80 other study(ies) available for fluconazole and anidulafungin

Article	Year
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Antifungal Agents; Candida; Candidiasis; Fungemia; Humans; Microbial Sensitivity Tests; Population Surveillance; Prevalence; Spain; Species Specificity	2008
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:6 Topics: Aged; Antifungal Agents; Candida glabrata; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fatal Outcome; Female; Fungal Proteins; Fungemia; Glucosyltransferases; Humans; Lipopeptides; Membrane Proteins; Microbial Sensitivity Tests; Mutation	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:8 Topics: Anidulafungin; Antifungal Agents; Candida; Candida glabrata; Caspofungin; Echinocandins; Fluconazole; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole	2008
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11 Topics: Aged; Aged, 80 and over; Antifungal Agents; Candida tropicalis; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fungemia; Hematologic Neoplasms; Humans; Lipopeptides; Male; Middle Aged	2008
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Echinocandins; Humans; Immunohistochemistry; Injections, Intraperitoneal; Lipopeptides; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Polymerase Chain Reaction	2009
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Antifungal Agents; Candida; Candidiasis; Data Collection; Disease Susceptibility; Greece; Humans; Intensive Care Units; Microbial Sensitivity Tests; Retrospective Studies	2009
Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:4 Topics: Anidulafungin; Animals; Antifungal Agents; beta-Glucans; Candida; Candidiasis; Disease Models, Animal; Echinocandins; Kidney; Male; Mice	2009
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5 Topics: Acremonium; Antifungal Agents; Aspergillus; Candida; Drug Resistance, Fungal; Echinocandins; Fungi; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Mycoses; Penicillium; Scedosporium; Spain	2009
Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:12 Topics: Aged; Antifungal Agents; Echinocandins; Fatal Outcome; Geotrichosis; Geotrichum; Humans; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Neutropenia	2009
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Ascomycota; Caspofungin; Chromoblastomycosis; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; In Vitro Techniques; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Nitriles; Pyridines; Pyrimidines; Triazoles; Voriconazole	2010
In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10 Topics: Anidulafungin; Animals; Antifungal Agents; Biofilms; Candida albicans; Candidiasis; Catheters; Echinocandins; Female; Rats; Rats, Sprague-Dawley	2010
In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:5 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Echinocandins; Fluconazole; Microbial Sensitivity Tests; Peptides, Cyclic	1997
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:9 Topics: Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Candida; Caspofungin; Cryptococcus neoformans; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Solubility; Solvents	1997
In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:11 Topics: Anidulafungin; Antifungal Agents; Candida; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Echinocandins; Fluconazole; Microbial Sensitivity Tests; Peptides, Cyclic	1997
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagnostic microbiology and infectious disease, 1998, Volume: 32, Issue:1 Topics: Amphotericin B; Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Blood; Candida; Caspofungin; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Lipopeptides; Peptides; Peptides, Cyclic; Sensitivity and Specificity; Serum Bactericidal Test	1998
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:9 Topics: Amphotericin B; Analysis of Variance; Anidulafungin; Animals; Antifungal Agents; Candida albicans; Candidiasis; Creatinine; Dose-Response Relationship, Drug; Echinocandins; Female; Fluconazole; Metabolic Clearance Rate; Microbial Sensitivity Tests; Neutropenia; Peptides, Cyclic; Potassium; Rabbits	1999
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:4 Topics: Amphotericin B; Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Azoles; Candida albicans; Caspofungin; Cryptococcus neoformans; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Polyenes	2000
Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. The Journal of antimicrobial chemotherapy, 2000, Volume: 46, Issue:3 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candidiasis; Drug Resistance, Microbial; Echinocandins; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Peptides, Cyclic	2000
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:2 Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Candidiasis; Candidiasis, Oral; Drug Resistance, Microbial; Echinocandins; Esophageal Diseases; Esophagus; Female; Fluconazole; Immunosuppression Therapy; Peptides, Cyclic; Pharyngeal Diseases; Rabbits; Saliva	2001
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2001, Volume: 7, Issue:1 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candidiasis; Culture Media; Echinocandins; Fluconazole; Flucytosine; Humans; Microbial Sensitivity Tests; Peptides, Cyclic; Reproducibility of Results	2001
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagnostic microbiology and infectious disease, 2002, Volume: 43, Issue:1 Topics: Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Candida; Caspofungin; Cell Division; Cryptococcus neoformans; Drug Resistance, Multiple, Fungal; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Lipopeptides; Logistic Models; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Time Factors	2002
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. Journal of clinical microbiology, 2005, Volume: 43, Issue:11 Topics: Anidulafungin; Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Microbial Sensitivity Tests; Peptides, Cyclic	2005
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:11 Topics: Algorithms; Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Area Under Curve; Candida glabrata; Candidiasis; Colony Count, Microbial; Dose-Response Relationship, Drug; Echinocandins; Female; Fluconazole; Mice; Microbial Sensitivity Tests; Neutropenia; Peptides, Cyclic	2006
Echinocandins--first-choice or first-line therapy for invasive candidiasis? The New England journal of medicine, 2007, Jun-14, Volume: 356, Issue:24 Topics: Anidulafungin; Antifungal Agents; Candidiasis; Echinocandins; Fluconazole; Fungemia; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Peptides, Cyclic	2007
Anidulafungin and fluconazole for candidiasis. The New England journal of medicine, 2007, Sep-27, Volume: 357, Issue:13 Topics: Anidulafungin; Antifungal Agents; Candidiasis; Confidence Intervals; Echinocandins; Fluconazole; Humans; Peptides, Cyclic; Research Design	2007
Anidulafungin and fluconazole for candidiasis. The New England journal of medicine, 2007, Sep-27, Volume: 357, Issue:13 Topics: Administration, Oral; Analysis of Variance; Anidulafungin; Antifungal Agents; Candidiasis; Catheterization, Central Venous; Echinocandins; Fluconazole; Humans; Infusions, Intravenous; Peptides, Cyclic; Time Factors	2007
Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagnostic microbiology and infectious disease, 2008, Volume: 62, Issue:1 Topics: Anidulafungin; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Random Amplified Polymorphic DNA Technique	2008
Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. International journal of antimicrobial agents, 2010, Volume: 36, Issue:1 Topics: Anidulafungin; Animals; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Disease Models, Animal; Echinocandins; Female; Fluconazole; Humans; Immunocompromised Host; Kidney; Lipopeptides; Mice; Mice, Inbred ICR; Neutropenia; Spleen; Treatment Outcome	2010
Case report 5: Intensive care unit patient assessed using the Candida Score. Mycoses, 2010, Volume: 53 Suppl 2 Topics: Accidents, Traffic; Adult; Anidulafungin; Antifungal Agents; Candida albicans; Candidiasis; Echinocandins; Fluconazole; Humans; Intensive Care Units; Male; Postoperative Complications; Severity of Illness Index; Treatment Outcome	2010
Case report 6: Candidaemia in a high risk liver transplant recipient. Mycoses, 2010, Volume: 53 Suppl 2 Topics: Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Bacteremia; Bronchitis; Candida albicans; Candidiasis; Echinocandins; Female; Fluconazole; Fungemia; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Liver Failure; Liver Transplantation; Postoperative Complications; Stenotrophomonas maltophilia; Transplantation; Treatment Outcome; Young Adult	2010
Clinical experience of anidulafungin for the treatment of patients with documented candidemia. Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:6 Topics: Anidulafungin; Antifungal Agents; Candida; Candidemia; Catheters, Indwelling; Cross Infection; Echinocandins; Female; Fluconazole; Humans; Italy; Male; Middle Aged; Pyrimidines; Retrospective Studies; Treatment Outcome; Triazoles; Voriconazole	2010
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. PharmacoEconomics, 2011, Volume: 29, Issue:8 Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Clinical Trials, Phase III as Topic; Critical Illness; Double-Blind Method; Drug Costs; Echinocandins; Female; Fluconazole; Health Resources; Hospital Costs; Hospitalization; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies	2011
Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:8 Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Australia; Candidiasis, Invasive; Cost-Benefit Analysis; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Models, Statistical; Randomized Controlled Trials as Topic; Treatment Failure; Treatment Outcome	2011
Anidulafungin treatment in a kidney transplant recipient with hepatic damage. Mycoses, 2011, Volume: 54 Suppl 4 Topics: Anidulafungin; Antifungal Agents; Chemical and Drug Induced Liver Injury; Echinocandins; Female; Fluconazole; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Middle Aged; Transplantation	2011
Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012, Volume: 18, Issue:2 Topics: Anidulafungin; Animals; Antifungal Agents; beta-Glucans; Blood; Blood Chemical Analysis; Candida albicans; Candidiasis, Invasive; Colony Count, Microbial; Disease Models, Animal; Echinocandins; Fluconazole; Mice; Mice, Inbred ICR; Neutropenia; Proteoglycans; Survival Analysis; Treatment Outcome	2012
The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates. Memorias do Instituto Oswaldo Cruz, 2012, Volume: 107, Issue:3 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida glabrata; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole	2012
In vitro synergy testing of anidulafungin with fluconazole, tioconazole, 5-flucytosine and amphotericin B against some Candida spp. Medicinal chemistry (Shariqah (United Arab Emirates)), 2012, Volume: 8, Issue:4 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Drug Synergism; Echinocandins; Fluconazole; Flucytosine; Imidazoles	2012
Species distribution and drug susceptibilities of Candida isolates in TSARY 2010. Diagnostic microbiology and infectious disease, 2013, Volume: 76, Issue:2 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Azoles; Candida; Drug Resistance, Multiple, Fungal; Echinocandins; Fluconazole; Hospitals; Humans; Microbial Sensitivity Tests; Pyrimidines; Taiwan; Triazoles; Voriconazole	2013
Hampered by historical paradigms--echinocandins and the treatment of Candida endocarditis. Mycoses, 2014, Volume: 57, Issue:5 Topics: Anidulafungin; Antifungal Agents; Candida; Echinocandins; Endocarditis; Fluconazole; Humans; Male; Middle Aged	2014
EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses, 2014, Volume: 57, Issue:6 Topics: Anidulafungin; Animals; Antifungal Agents; Candida; Echinocandins; Europe; Fluconazole; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests	2014
Activities of fluconazole, caspofungin, anidulafungin, and amphotericin B on planktonic and biofilm Candida species determined by microcalorimetry. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:5 Topics: Amphotericin B; Anidulafungin; Biofilms; Calorimetry; Candida; Caspofungin; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Plankton	2014
Anidulafungin-induced alopecia. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:5 Topics: Adult; Alopecia; Anidulafungin; Antifungal Agents; Candidiasis; Drug Therapy, Combination; Echinocandins; Female; Fluconazole; Humans; Lipopeptides; Micafungin	2014
Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:8 Topics: Anidulafungin; Antifungal Agents; Candida glabrata; Candidemia; Caspofungin; Drug Resistance, Multiple, Fungal; Echinocandins; Fluconazole; Fungal Proteins; Glucosyltransferases; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Mutation; United States	2014
Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015, Volume: 34, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candidemia; Caspofungin; Child; Child, Preschool; Echinocandins; Female; Fluconazole; Health Care Costs; Hospitalization; Humans; Infant; Intensive Care Units; Lipopeptides; Male; Micafungin; Middle Aged; Treatment Outcome; Young Adult	2015
In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Mycoses, 2015, Volume: 58, Issue:5 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Caspofungin; Echinocandins; Epidermophyton; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Naphthalenes; Nitriles; Pyridines; Terbinafine; Tinea; Triazoles; Trichophyton; Voriconazole	2015
Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Critical care (London, England), 2015, Feb-04, Volume: 19 Topics: Aged; Anidulafungin; Antifungal Agents; Caspofungin; Critical Illness; Drug Monitoring; Echinocandins; Europe; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Middle Aged	2015
Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution. BMC infectious diseases, 2015, Jul-03, Volume: 15 Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Anidulafungin; Antifungal Agents; beta-Glucans; Candida; Candida albicans; Candida glabrata; Candidiasis; Candidiasis, Invasive; Carrier State; Caspofungin; Critical Care; Echinocandins; Female; Fluconazole; Humans; Incidence; Intensive Care Units; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Sensitivity and Specificity; Singapore; Tertiary Care Centers; Voriconazole	2015
In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Ascomycota; Caspofungin; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Mycoses; Nitriles; Pyridines; Triazoles; Voriconazole	2015
Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis. BMC infectious diseases, 2015, Oct-26, Volume: 15 Topics: Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Caspofungin; Cost-Benefit Analysis; Drug Costs; Echinocandins; Fluconazole; Humans; Intensive Care Units; Length of Stay; Lipopeptides; Micafungin; Models, Economic; Treatment Outcome; United Kingdom	2015
Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections. Mycoses, 2016, Volume: 59, Issue:3 Topics: Administration, Intravenous; Adult; Aged; Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Caspofungin; Critical Illness; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Micafungin; Middle Aged; Multivariate Analysis; Retrospective Studies	2016
Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey. Annals of clinical microbiology and antimicrobials, 2016, May-31, Volume: 15, Issue:1 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Species Specificity; Triazoles; Voriconazole	2016
First isolation of Candida wangnamkhiaoensis from the blood of immunocompromised paediatric patient. Mycoses, 2016, Volume: 59, Issue:11 Topics: Anidulafungin; Antifungal Agents; Candida; Candidemia; Caspofungin; Child, Preschool; DNA, Ribosomal Spacer; Echinocandins; Fluconazole; Humans; Hyphae; Immunocompromised Host; Lipopeptides; Male; Phylogeny; Polymerase Chain Reaction; Sequence Alignment; Voriconazole	2016
Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent Candida spp. Journal of medical microbiology, 2016, Volume: 65, Issue:12 Topics: Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis; Candidiasis, Invasive; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Respiratory System; Urine	2016
Changing epidemiology of candidaemia in Australia. The Journal of antimicrobial chemotherapy, 2017, 04-01, Volume: 72, Issue:4 Topics: Anidulafungin; Antifungal Agents; Australia; Azoles; Candida; Candida glabrata; Candida tropicalis; Candidemia; Caspofungin; Drug Resistance, Fungal; Echinocandins; Female; Fluconazole; Humans; Incidence; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Sequence Analysis, DNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Triazoles; Voriconazole	2017
A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes. PloS one, 2017, Volume: 12, Issue:4 Topics: Adolescent; Adult; Aged; Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candidemia; Child; Child, Preschool; Drug Resistance, Fungal; Echinocandins; Female; Fluconazole; Humans; Incidence; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Peru; Prospective Studies; Triazoles; Voriconazole; Young Adult	2017
Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species. BMC infectious diseases, 2017, 07-10, Volume: 17, Issue:1 Topics: Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidemia; Candidiasis, Invasive; Caspofungin; Cost-Benefit Analysis; Echinocandins; Economics, Pharmaceutical; Fluconazole; Humans; Lipopeptides; Micafungin; Taiwan; Treatment Outcome	2017
Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey. Mycoses, 2017, Volume: 60, Issue:11 Topics: Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Cost-Benefit Analysis; Decision Support Techniques; Double-Blind Method; Echinocandins; Fluconazole; Humans; Randomized Controlled Trials as Topic; Treatment Failure; Treatment Outcome; Turkey	2017
Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen Candida glabrata. Scientific reports, 2017, 08-22, Volume: 7, Issue:1 Topics: Anidulafungin; Antifungal Agents; Candida glabrata; Candidiasis, Invasive; Drug Resistance, Fungal; Fluconazole; Fungal Proteins; Genetic Fitness; Glucosyltransferases; Humans; Microbial Sensitivity Tests; Microbial Viability; Mutation; Phenotype; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2017
Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia. Scientific reports, 2019, 03-07, Volume: 9, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Candidemia; Caspofungin; Child; Child, Preschool; Female; Fluconazole; Flucytosine; Humans; Itraconazole; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Triazoles; Voriconazole; Young Adult	2019
Nitroglycerin-Citrate-Ethanol Catheter Lock Solution Is Highly Effective for Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Biofilms; Candida; Caspofungin; Catheter-Related Infections; Catheters; Citric Acid; Ethanol; Fluconazole; Micafungin; Nitroglycerin; Pharmaceutical Solutions; Voriconazole	2019
MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and anidulafungin and 35 uncommon pathogenic yeast species from the UK determined using the CLSI broth microdilution method. The Journal of antimicrobial chemotherapy, 2020, 05-01, Volume: 75, Issue:5 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Fluconazole; Flucytosine; Humans; Itraconazole; Microbial Sensitivity Tests; Phylogeny; United Kingdom; Voriconazole	2020
Anidulafungin treatment for fluconazole-resistant Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2021, Volume: 41, Issue:4 Topics: Adult; Anidulafungin; Antifungal Agents; Azoles; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluconazole; Humans; Microbial Sensitivity Tests; Turkey	2021
Preventing Emerging microbes & infections, 2020, Volume: 9, Issue:1 Topics: Anidulafungin; Animals; Antibodies, Monoclonal; Antifungal Agents; Caco-2 Cells; Candida albicans; Candidemia; Disease Models, Animal; Drug Synergism; Endothelial Cells; Epithelial Cells; Female; Fluconazole; Fungal Proteins; Human Umbilical Vein Endothelial Cells; Humans; Mice; Phosphopyruvate Hydratase; Plasminogen; Protein Binding; Protein Structure, Secondary	2020
Axillary Digital Thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil. Mycoses, 2021, Volume: 64, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Brazil; Candida; Candidiasis; COVID-19; Critical Care; Disease Outbreaks; Disease Transmission, Infectious; Female; Fluconazole; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prevalence; SARS-CoV-2; Thermometers; Voriconazole	2021
Antifungal activity of nitroxoline against Candida auris isolates. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021, Volume: 27, Issue:11 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida auris; Fluconazole; Humans; Microbial Sensitivity Tests; Nitroquinolines	2021
Narrow mutational signatures drive acquisition of multidrug resistance in the fungal pathogen Candida glabrata. Current biology : CB, 2021, 12-06, Volume: 31, Issue:23 Topics: Anidulafungin; Antifungal Agents; Candida glabrata; Drug Resistance, Fungal; Drug Resistance, Multiple; Fluconazole; Microbial Sensitivity Tests; Mutation	2021
Antifungal susceptibility profile of invasive Journal of medical microbiology, 2021, Volume: 70, Issue:12 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida glabrata; Candidemia; Caspofungin; Cross-Sectional Studies; Drug Resistance, Fungal; Fluconazole; Humans; Micafungin; Pakistan; Retrospective Studies; Tertiary Care Centers	2021
Genotyping and Drug Resistance Profile of Clinical Isolates of Candida albicans from Vulvovaginal Candidiasis in the Eastern China. Mycopathologia, 2022, Volume: 187, Issue:2-3 Topics: Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluconazole; Genotype; Humans; Microbial Sensitivity Tests; Voriconazole	2022
Early phenotypic detection of fluconazole- and anidulafungin-resistant Candida glabrata isolates. The Journal of antimicrobial chemotherapy, 2022, 05-29, Volume: 77, Issue:6 Topics: Anidulafungin; Antifungal Agents; Candida glabrata; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Microbial Sensitivity Tests	2022
Multiple colony antifungal susceptibility testing detects polyresistance in clinical Candida cultures: a European Confederation of Medical Mycology excellence centers study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:9 Topics: Anidulafungin; Antifungal Agents; Candida; Candida albicans; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Mycology	2022
In vitro activity of 23 antifungal drugs against 54 clinical and environmental Aspergillus oryzae isolates. Mycoses, 2022, Volume: 65, Issue:11 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Aspergillus oryzae; Clotrimazole; Econazole; Fluconazole; Griseofulvin; Humans; Itraconazole; Ketoconazole; Miconazole; Microbial Sensitivity Tests; Natamycin; Nystatin; Terbinafine; Tolnaftate; Voriconazole	2022
[One-Year Candida Data of the Central Mycology Laboratory: Which Sample, Which Species, How Resistant?] Mikrobiyoloji bulteni, 2022, Volume: 56, Issue:3 Topics: Anidulafungin; Antifungal Agents; Candida; Drug Resistance, Fungal; Fluconazole; Humans; Micafungin; Microbial Sensitivity Tests; Mycology; Voriconazole	2022
The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms. Mycopathologia, 2023, Volume: 188, Issue:1-2 Topics: Amphotericin B; Anidulafungin; Biofilms; Caspofungin; Echinocandins; Fluconazole; Micafungin	2023
Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia. Enfermedades infecciosas y microbiologia clinica (English ed.), 2023, Volume: 41, Issue:10 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Biofilms; Candida; Candida albicans; Candidemia; Deoxycholic Acid; Fluconazole; Humans	2023
Identification and susceptibility testing of oral candidiasis in advanced cancer patients. BMC oral health, 2023, 04-18, Volume: 23, Issue:1 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis, Oral; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Neoplasms	2023
Rapid automated antifungal susceptibility testing system for yeasts based on growth characteristics. Frontiers in cellular and infection microbiology, 2023, Volume: 13 Topics: Anidulafungin; Antifungal Agents; Candida; Caspofungin; Fluconazole; Micafungin; Microbial Sensitivity Tests; Reproducibility of Results; Voriconazole; Yeasts	2023
A 3-year study of Frontiers in cellular and infection microbiology, 2023, Volume: 13 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candidemia; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Neoplasms	2023
In vitro combination of antifungal drugs with tacrolimus (FK506) holds promise against clinical Candida species, including Candida auris. Medical mycology, 2023, Jul-06, Volume: 61, Issue:7 Topics: Anidulafungin; Animals; Antifungal Agents; Candida; Candida auris; Candida glabrata; Candida parapsilosis; Caspofungin; Echinocandins; Fluconazole; Itraconazole; Microbial Sensitivity Tests; Tacrolimus	2023
Assessing the impact of prophylactic anidulafungin during remission induction of acute myeloid leukemia - A propensity-score matching analysis. Journal de mycologie medicale, 2023, Volume: 33, Issue:4 Topics: Adult; Anidulafungin; Antifungal Agents; Fluconazole; Humans; Leukemia, Myeloid, Acute; Propensity Score; Remission Induction; Retrospective Studies	2023